Status:
RECRUITING
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Lead Sponsor:
UConn Health
Collaborating Sponsors:
National Institute on Aging (NIA)
University of Connecticut
Conditions:
Frailty
Mild Cognitive Impairment
Eligibility:
All Genders
65-80 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it...
Detailed Description
Chronic diseases and associated declines in physical and cognitive performance contribute greatly to lost independence with aging. In addition to a lack of effective interventions other than exercise ...
Eligibility Criteria
Inclusion
- men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
- good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
Exclusion
- A vaccination in past two weeks
- Recent acute infection three weeks prior to enrollment
- Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
- Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
- Severe autoimmune disease requiring biological therapy
- Major severe illness and/or Hospitalization in past 3 months
- On warfarin or other medications that are considered a blood thinner
- Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
- Known bleeding disorder
- Any conditions that would impair the function to perform grip strength test
- include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.
- Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
- Baseline ECG QTc \>450 ms in men and QTc \>460 ms in women
- Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
Key Trial Info
Start Date :
October 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06027554
Start Date
October 7 2024
End Date
February 1 2028
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UConn Health
Farmington, Connecticut, United States, 06030